Jiuqiang Biotech: “Jiujiang Bonds Transfer” suspends share conversion during the implementation of equity distribution
Beijing Jiuqiang Biotechnology Co., Ltd. announced that the company will soon implement the company's 2023 equity distribution. From April 24, 2023 to the 2023 equity distribution share registration date, “Jiuqiang Bonds Transfer” will suspend share conversion and resume share conversion from the first trading day after the 2023 equity distribution share registration date.
Express News | The net inflow of the 8-share mega-order exceeded 100 million yuan
Express News | Shuanglu Pharmaceutical: Net profit of 70.1346 million yuan in the first quarter, a year-on-year decrease of 65.27%
Changchun Hi-Tech (000661.SZ) subsidiary's application for marketing licensing of Baike Bio's live attenuated nasal spray influenza vaccine was accepted
Changchun Hi-Tech (000661.SZ) issued an announcement. The company's subsidiary Changchun Baike Biotechnology Co., Ltd. (abbreviated as “...
Pepsis (301080.SZ): Net profit of 306.721 million yuan in the first quarter decreased by 31.91% year-on-year
On April 23, GLONGHUI (301080.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 146 million yuan, up 6.67% year on year; net profit attributable to shareholders of listed companies was 306.721 million yuan, down 31.91% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 30.2819 million yuan, down 32.12% year on year; basic earnings per share were 0.2561 yuan.
Yuandong Biology (688513): Building the foundation for large single refined cannabis products+internationalization of formulations drives long-term growth
Matters: The company announced its 2023 annual report, achieving revenue of 1,117 million yuan (-4.6%), net profit attributable to mother of 227 million yuan (-8.1%), net profit after deduction of 158 million yuan (-4.3%), performance omitted